Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec.
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Baldassarre, Maria Pompea Antonia;
2017-01-01
Abstract
Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
nejmoa1615692.pdf
accesso aperto
Tipologia:
PDF editoriale
Dimensione
316.53 kB
Formato
Adobe PDF
|
316.53 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
